Tachibana K, Inoue Y, Nishiyama A et al. Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: Serum IL-7 as a prognostic marker. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 113-22.
Asami K, Kawahara M, Atagi S et al. Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 2011; 73: 211-6.
Funakoshi Y, Sawabata N, Takeuchi Y et al. Clinical implication of pulmonary excision for undiagnosed peripheral lung cancer. Interact Cardiovasc Thorac Surg 2011; 13: 485-9.
Hayashi S, Oji Y, Kanai Y,et al. Low Wilms' tumor gene expression in tumor tissues predicts poor prognosis in patients with non-small-cell lung cancer. Cancer Invest. 2011;30:165-71.
Asami K, Koizumi T, Hirai K,et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer. 2011,12:387-92.
Akira M, Inoue Y, Arai T, et al. Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax. 2011,66:61-5.
Okada M, Kita Y, Kanamaru N, et al. Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice. Clin Dev Immunol. 2011;2011:404929.
Okada M, Kita Y, Nakajima T,et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin. 2011 Jan-Feb;7 Suppl:60-7.
Okada M, Kita Y, Nakajima T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol. 2011;2011:549281.
Kita Y, Okada M, Nakajima T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin. 2011 Jan-Feb;7 Suppl:108-14.
Kubo A, Koh Y, Kawaguchi T, et al. Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. Intern Med. 2011;50:745-8.
